CDH17-Targeted Tumor-Killing Immunotherapeutics
Safe: Our novel CAR technology will enable CAR T cells to specifically attack tumors and not normal tissues
Effective: CDH17 is a tumor antigen abundant in cancer that has been shown to be effectively targeted in animal studies
Fast-Track Launch: CDH17-CAR T cells are expected to launch in Greater China markets late 2018
Solid tumors can be eliminated by CAR cells in the clinic; there has been recent success with CAR cell treatment of neuroblastoma (brain cancer).
CDH17-CAR-T (Chimeric Antigen Receptor-T cell)
Arbele is developing novel CAR-T cells targeting CDH17 antigen expressed on various cancer types including liver, stomach, colon, pancreas, esophagus and lung cancers
CDH17-CD3 Bi-Specific MAbs (or BiTE)
BiTE (a trademark of Amgen) therapeutics, a bi-specific mAb that forms a link between tumor and T cells, causing cancer cell death
Proprietary and Technology Niche
Chimeric Antigen Receptor (CAR) technology directs T and NK (natural killer) cells to recognize cancer cells based on expression of specific cell surface proteins.
The use of bispecific antibodies, targeting two tumor antigens for cancer treatment. This approach evolves to BiTE therapeutics, a bi-specific mAb that forms a link between tumor and T cells, causing cancer cell death.
Using high-throughput and cutting-edge DNA sequencing technology, we can identify the oncogenes and mutations unique in patient's samples - tumor and liquid biopsies for early diagnosis and precision treatments.